Seungyeup Han and Byung Ha Chung contributed equally to this article as co-corresponding author.
This study evaluated the impact of acute kidney injury (AKI) on posttransplant clinical outcomes for deceased donor (DD) kidney transplantation (KT) using the Kidney Donor Profile Index (KDPI) system.
Overall, 657 kidney transplant recipients (KTRs) receiving kidneys from 526 DDs from four transplant centers were included. We divided them into the high and low KDPI donor groups by 65%, the KDPI score, and both groups were subdivided into the AKI-DDKT and non-AKI-DDKT subgroups according to AKI in DDs.
There was no significant difference in the incidence of delayed graft function (DGF) between the high and low KDPI-KTR groups; however, the AKI-DDKT subgroup showed significantly higher incidence of DGF than the non-AKI-DDKT subgroup in both groups (p = 0.001, p < 0.001, respectively). The death-censored graft survival rate was significantly lower in the high KDPI-KTR group than in the low KDPI-KTR group (p = 0.005). Only in the high KDPI-KTR group, the death-censored graft survival rate was significantly lower in the KT from DDs with AKI stage 3 than KT from DDs with non-AKI or AKI stage 1 or 2 (p = 0.040). The interaction between AKI stage 3 in DDs and high KDPI on the allograft outcome was significant (p = 0.002).
KTs from DDs with AKI stage 3 showed an adverse impact on the allograft outcome in the high KDPI-KTR group. Therefore, DDs with a high KDPI score should be managed carefully so that severe AKI does not occur prior to KT.
Although one of the biggest drawbacks of kidney transplantation (KT) is the problem of organ shortage, the number of discarded kidneys still increases worldwide [
Several researches have recently been published regarding the clinical impact of KT from deceased donors (DDs) with acute kidney injury (AKI) in deceased donor KT (DDKT) [
Recently, Koyawala and Parikh [
A total of 657 KTRs receiving kidneys from 526 DDs between October 1996 and December 2017 from four transplant centers (Seoul St. Mary’s Hospital, Uijeongbu St. Mary’s Hospital, Daejeon St. Mary’s Hospital, and Keimyung University Dongsan Hospital) were included. We divided them into the high and low KDPI donor groups by 65%, which is the median value of the KDPI score, and both groups were subdivided into the AKI-DDKT and non-AKI-DDKT subgroups according to AKI in DDs. AKI in DDs was defined and staged according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria as described in previous reports [
The medical records of the study population were retrospectively analyzed. We investigated the data of DDs: age, sex, height, weight, body mass index (BMI, kg/m2), ethnicity, history of diabetes mellitus (DM) and hypertension (HTN), causes of brain death, serum creatinine, estimated glomerular filtration rate (eGFR) by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) at baseline and the admission day and prior to KT, hepatitis C virus state, and donation after cardiac death. When serum creatinine was normal at the time of admission, the serum creatinine at admission was defined as baseline creatinine even if there was no previous baseline creatinine, and serum creatinine was measured at least 2 to 3 times until KT. AKI was defined by the KDIGO guideline based on the serum creatinine at the time of admission regardless of the presence or absence of a baseline creatinine. CKD was defined when estimated GFR less than 60 mL/min/1.73 m2 continued for 3 months after measuring baseline creatinine. We used the ECD criteria according to the United Network for Organ Sharing for the definition of marginal donors [
Biopsy-proven acute rejection (BPAR) was diagnosed according to the Banff classification [
The primary outcome of this study was to investigate the impact of AKI in DDs on the death-censored allograft survival between the high and low KDPI-KTR groups. Therefore, we compared the death-censored allograft survival between the AKI-DDKT and non-AKI-DDKT subgroups in both high and low KDPI-KTR groups and analyzed the interaction between AKI and high KDPI score. The secondary outcomes were to investigate the incidences of DGF and BPAR and changes in allograft function during the first year after KT (1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after KT; assessed by eGFR, calculated using the CKD-EPI [
This study was approved by the Institutional Review Boards (IRBs) of Seoul St. Mary’s Hospital (No. XC15RIMI0061K), Uijeongbu St. Mary’s Hospital (No. XC15RIMI0061U), Daejeon St. Mary’s Hospital (No. XC15RIMI0061K), and Dongsan Hospital, Keimyung University School of Medicine (No. 2020-05-047). The requirements for informed consent were waived by the IRBs of the aforementioned four centers because the use of the patient’s data for research was informed to all donors’ families and all recipients prior to KT to protect the personal information. Our study did not contain any distinguishable personal information, and all methods were performed according to the relevant guidelines and regulations.
Continuous variables are expressed as mean ± standard deviation or median (interquartile range) and analyzed using the Student t test or the Mann-Whitney test. Categorical variables are expressed as count and percentage and analyzed using the chi-square test and Fisher exact test. The death-censored graft survival and patient survival rates were analyzed using the Kaplan-Meier curves and log-rank tests. All missing data were excluded. The Cox proportional hazards regression analysis was performed to investigate the relationship of the KDPI score and AKI for the clinical outcomes in DDKT, considering the confounding factors such as recipient age, transplant year (1996–2005 vs. 2006–2010 vs. 2011–2017), transplant center, recipient HTN, and acute rejection. Interaction effects between AKI and high KDPI score were explored by adding interaction terms to the Cox proportional hazards model with backward elimination of variables. In other words, AKI * high KDPI score as an interaction effect was included in the Cox proportional hazards model. The p-values less than 0.05 were considered statistically significant. All statistical analyses were performed using IBM SPSS version 21.0 (IBM Corp., Armonk, NY, USA).
The median follow-up duration of the study population was 48.0 months (interquartile range, 22.3–68.0). The mean age of the high KDPI donor group was significantly higher than that of the low KDPI donor group (55.0 ± 8.9 years vs. 35.5 ± 12.2 years, p < 0.001). The proportions of donors with HTN, DM, and death due to cerebrovascular accident (CVA) were significantly higher in the high KDPI donor group than in the low KDPI donor group (37.4% vs. 4.1%, p < 0.001; 17.1% vs. 2.1%, p < 0.001; 76.3% vs. 62.1%, p < 0.001, respectively). The baseline and allocation CKD-EPI eGFRs in DDs were significantly lower in the high KDPI donor group than in the low KDPI donor group (79.7 ± 20.1 mL/min/1.73 m2 vs. 87.8 ± 28.9 mL/min/1.73 m2, p = 0.001; 51.6 ± 29.6 mL/min/1.73 m2 vs. 94.9 ± 44.6 mL/min/1.73 m2, p < 0.001). The proportion of DDs with CKD stage 3 or above at allocation was significantly higher in the high KDPI donor group than in the low KDPI donor group (67.7% vs. 30.9%, p < 0.001). The proportion of AKI was also significantly higher in the high KDPI donor group than in the low KDPI donor group (69.3% vs. 42.8%, p < 0.001). The proportion of ECD donors was significantly higher in the high KDPI donor group than in the low KDPI donor group (57.6% vs. 0.4%, p < 0.001). There were no significant differences in donor sex and BMI between the high and low KDPI donor groups (
In corresponding recipients, the mean age was also higher in the high KDPI-KTR group than in the low KDPI-KTR group (51.3 ± 10.1 years vs. 47.6 ± 9.8 years, p < 0.001). The proportions of KTRs with DM and use of antithymocyte globulin for induction immunosuppressant were significantly higher in the high KDPI-KTR group than in the low KDPI-KTR group (24.3% vs. 17.2%, p = 0.028; 33.7% vs. 25.1%, p = 0.017), but the proportion of retransplantation was significantly higher in the low KDPI-KTR group than in the high KDPI-KTR group (14.1% vs. 7.4%, p = 0.008). The mean HLA mismatch number was significantly higher in the high KDPI-KTR group than in the low KDPI-KTR group (3.8 ± 1.5 vs. 3.5 ± 1.5, p = 0.014). There was no significant difference in the distribution of recipient sex, dialysis duration before KT, cold ischemic time, and proportion of PRA > 50% between the high and low KDPI-KTR groups (
In the high KDPI donor group, the proportions of male sex and cause of donor death by CVA were significantly higher in the AKI donor subgroup compared with those in the non-AKI donor subgroup (71.3% vs. 55.6%, p = 0.016; 78.7% vs. 70.9%, p = 0.024). The proportions of HTN and eGFR at baseline and allocation were significantly lower in the AKI donor subgroup compared with those in the non-AKI donor subgroup (30.9% vs. 51.9%, p = 0.002; 45.4 ± 26.6 vs. 81.0 ± 27.0, p < 0.001; 34.0 ± 21.0 vs. 77.7 ± 24.7, p < 0.001). On the contrary, in the low KDPI donor group, the BMI and proportion of CKD stage 3 or above were significantly higher in the AKI donor subgroup compared with those in the non-AKI donor subgroup (24.1 ± 4.0 vs. 22.2 ± 3.9, p < 0.001; 48.7% vs. 36.4%, p = 0.046), but eGFRs at baseline and allocation were significantly lower in the AKI donor subgroup compared with those in the non-AKI donor subgroup (59.0 ± 36.0 vs. 102.3 ± 34.5, p < 0.001; 50.5 ± 32.0 vs. 106.7 ± 31.4, p < 0.001).
In corresponding recipients, the proportions of antithymocyte globulin were significantly higher in the AKI-DDKT subgroup compared with those in the non-AKI-DDKT subgroup in both high and low KDPI-KTR groups (41.0% vs. 16.2%, p < 0.001; 33.8% vs. 17.5%, p = 0.001, respectively). There was no significant difference in the distribution of recipient age, sex, HTN, DM, dialysis duration before KT, previous KT, cold ischemic time, main immunosuppressant, and proportion of PRA > 50% between the high and low KDPI-KTR groups (
The incidence of DGF was not significantly different between the high and low KDPI-KTR groups (18.0% vs. 18.2%, p > 0.999) (
The incidence of BPAR within the first year after KT did not differ significantly between the high and low KDPI-KTR groups (12.7% vs. 12.5%, p > 0.999) (
Allograft function for 12 months (1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months) after KT was significantly lower in the high KDPI-KTR group compared with that in the low KDPI-KTR group (39.4 ± 28.3 vs. 56.2 ± 33.3, p < 0.001; 52.0 ± 24.4 vs. 68.1 ± 29.0, p < 0.001; 48.4 ± 20.8 vs. 63.5 ± 23.6, p < 0.001; 56.0 ± 18.8 vs. 72.5 ± 20.5, p < 0.001; 54.8 ± 18.4 vs. 71.5 ± 20.1, p < 0.001; 57.6 ± 19.7 vs. 75.0 ± 22.5, p < 0.001) (
A total of 49 cases (49 of 657, 7.5%) of graft failure developed, including 31 cases (4.7%) in the high KDPI-KTR group (20 and 11 patients in the AKI-DDKT and non-AKI-DDKT subgroups, respectively) and 18 cases (2.7%) in the low KDPI-KTR group (7 and 11 patients in the AKI-DDKT and non-AKI-DDKT subgroups, respectively). There were no significant differences in the distribution of the causes of allograft failure between the AKI-DDKT and non-AKI-DDKT subgroups in the high or low KDPI-KTR group (
A total of 33 patients (33 of 657, 5.0%) died, 18 cases (2.7%) of whom were in the high KDPI-KTR group (14 and 4 patients in the AKI-DDKT and non-AKI-DDKT subgroups, respectively) and 15 cases (2.3%) of whom were in the low KDPI-KTR group (3 and 12 patients in the AKI-DDKT and non-AKI-DDKT subgroups, respectively). There were no significant differences in the distribution of the cause of patient death between the AKI-DDKT and non-AKI-DDKT subgroups in the high or low KDPI-KTR group (
For a long time, the ECD criteria have been used to determine to accept or discard DD kidneys. Our previous study reported that the allograft outcome was poor when ECD was accompanied by AKI [
First, we compared the clinical characteristics of the high and low KDPI donors. The mean age of donor at KT and proportions of HTN, DM, CVA, AKI, and ECD were significantly higher, and the mean CKD-EPI eGFRs at baseline and allocation were significantly lower in the high KDPI donors than in the low KDPI donors perhaps because the KDPI score contains donor age, creatinine, history of HTN and DM, and cause of death (CVA) [
In the short-term clinical outcomes between the high and low KDPI-KTR groups, the occurrence of AKI in high or low KDPI score led to a higher incidence of DGF after KT. These findings suggested that AKI or high KDPI score on DDs was an independent risk factor for DGF, and this result is consistent with previous studies [
A research reported that allograft function in the early period after KT was significantly lower in the KT from marginal DDs [
Our main hypothesis is that AKI in DDs has a different impact on the long-term allograft survival in the high and low KDPI-KTR groups. The death-censored graft survival rate was significantly lower in the high KDPI-KTR group than in the low KDPI-KTR group. However, in the subgroup analysis, there was no significant difference in the death-censored graft survival rates between the AKI-DDKT and non-AKI-DDKT subgroups in the high or low KDPI-KTR group. Interestingly, in the high KDPI-KTR group, AKI stage 3 was the lowest in the death-censored graft survival rate in comparison with non-AKI and AKI stages 1 and 2 but not in the low KDPI-KTR group. In the multivariate analysis using the Cox proportional hazards regression model, the coexistence of high KDPI and AKI stage 3 in DDs was a significant contributor to allograft failure, and we found a significant interaction between high KDPI and AKI stage 3 in DDs on allograft failure as suggested in
In contrast to the death-censored allograft survival rate, the patient survival rate was not significantly different between the high and low KDPI-KTR groups, and the distribution of the cause of death did not depend on the KDPI score. There was also no significant difference in the patient survival rate between the AKI-DDKT and non-AKI-DDKT subgroups in the high or low KDPI-KTR group. It may be because the number of patient death was too small to evaluate the impact of AKI in DDs for the patient survival in the high and low KDPI-KTR groups. Therefore, a large, well-designed prospective study is required to overcome the small sample size.
Both donor and recipient factors are important in the prognosis of DDKT, but donor factors are particularly important for short-term outcomes such as DGF or allograft function at the time of early stage after KT. Therefore, an allocation system for selecting an appropriate donor is currently needed above all. In 2014, the KDPI score was introduced as a new allocation system in the US and it has been studied not only in the US but also in various countries around the world. We demonstrated that the presence of AKI in ECDs significantly impacted the long-term allograft outcomes of KTRs [
Although the KDPI score is helpful to evaluate the effect of the DD factors and predict the prognosis of posttransplant clinical outcomes, there were some limitations in our studies. First, these were retrospective studies, so the KDPI score was calculated retrograde after KT. Therefore, well-designed large-scale prospective study is needed because the KDPI score is a prospective predictor. Second, it is known that the predictive power of the KDPI is only moderate (c-statistic = 0.60). Third, all donor factors associated with graft outcomes are not included with pathologic findings. Fourth, there is a selection bias for the prognosis of KT since clinicians want to selectively perform DDKT with good quality of kidney although they consider the KDPI score.
Our study has some limitations like our previous reports using this cohort. First, because this was a retrospective cohort study, this could have selection bias. However, we analyzed the medical records of four centers considering the characteristics such as multiple transplant centers and transplant year without the loss of KTRs during the study period in the multivariate analysis. Second, because KT from both kidneys in the same transplant center was not performed, the clinical outcome of the contralateral kidney transplanted in the other transplant center could not be known. The tracking system for all transplanted or discarded kidneys is needed to overcome this problem. Lastly, the Korean allocation rule has been applied for the allocation when the brain death donor occurred. Because the KDPI system has not been validated in Korea, it has not been used in the real world. We only used the KDPI score for the research retrospectively. In spite of these limitations, this study is valuable because it is a very useful research as basic data for improving the allocation system, given the reality that the allocation criteria are not clear although DDKT with donor AKI is expanding year by year in Korea.
In conclusion, KTs from DDs with AKI stage 3 showed an adverse impact on the allograft outcome in the high KDPI-KTR group. Therefore, although AKI occurs in DDs with a high KDPI score, it is recommended to perform KT from donor kidney with AKI stages 1 and 2, and it would be better to judge more carefully for donor kidney with AKI stage 3 using additional tools such as procurement biopsy. In addition, donor management should be performed more carefully not to proceed to AKI stage 3 during donor management before allocation.
All authors have no conflicts of interest to declare.
This study was supported by a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI20C0317) and also was supported by the First Research Support Project of the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT in 2018 (NRF-2017R1C1B5076739).
Conceptualization: All authors
Data curation: WYP, YKC, YSK, KJ, CWY
Funding acquisition: WYP, BHC
Investigation: YKC, YSK, KJ
Writing–original draft: WYP, SH, BHC
Writing–review & editing: WYP, CWY, SH, BHC
All authors read and approved the final manuscript.
Deceased donors were classified into high KDPI and low KDPI donor groups based on the median value of KDPI of 65%. In addition, KTRs were divided into AKI-KT and non-AKI-KT subgroups.
KDPI, Kidney Donor Profile Index; KTRs, kidney transplant recipients; AKI, acute kidney injury; KT, kidney transplantation.
(A, B) Comparison of DGF incidence rates (A) between high KDPI-KTR and low KDPI-KTR groups and (B) between AKI-DDKT and non-AKI-DDKT subgroups in the high KDPI-KTR or low KDPI-KTR group. (C, D) Comparison of BPAR incidence rate (C) between high KDPI-KTR and low KDPI-KTR groups and (D) between AKI-DDKT and non-AKI-DDKT subgroups in the high KDPI-KTR or low KDPI-KTR group. (E-G) Comparison of the change in allograft function after kidney transplant (E) between high KDPI-KTR and low KDPI-KTR groups, (F) between AKI-DDKT and non-AKI-DDKT subgroups in the high KDPI-KTR group, and (G) between AKI-DDKT and non-AKI-DDKT subgroups in the low KDPI-KTR group.
AKI, acute kidney injury; BPAR, biopsy-proven acute rejection; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; DDKT, deceased donor kidney transplantation; DGF, delayed graft function; KDPI, Kidney Donor Profile Index; KTR, kidney transplant recipient.
*p < 0.001 vs. non-AKI-DDKT.
(A–C) Comparison of the death-censored graft survival rate (A) between the high KDPI-KTR and low KDPI-KTR groups, (B) between AKI-DDKT and non-AKI-DDKT subgroups in the high KDPI-KTR group, and (C) between AKI-DDKT and non-AKI-DDKT subgroups in the low KDPI-KTR group. (D, E) Comparison of the death-censored graft survival rate according to the AKI stage (D) in the high KDPI-KTR group and (E) in the low KDPI-KTR group.
AKI, acute kidney injury; DDKT, deceased donor kidney transplantation; KDPI, Kidney Donor Profile Index; KTR, kidney transplant recipient.
Comparison of (A) between the high KDPI-KTR and low KDPI-KTR groups, (B) between AKI-DDKT and non-AKI-DDKT subgroups in the high KDPI-KTR group, and (C) between AKI-DDKT and non-AKI-DDKT subgroups in the low KDPI-KTR group.
AKI, acute kidney injury; DDKT, deceased donor kidney transplantation; KDPI, Kidney Donor Profile Index; KTR, kidney transplant recipient.
Comparison of clinical and laboratory parameters between high KDPI donor (or recipient) and low KDPI donor (or recipient)
Variable | High KDPI | Low KDPI | p-value |
---|---|---|---|
Donor | 257 | 269 | |
Age at KT (yr) | 55.0 ± 8.9 | 35.5 ± 12.3 | <0.001 |
Sex, male:female | 171:86 | 197:72 | 0.106 |
BMI (kg/m2) | 23.1 ± 3.2 | 22.6 ± 3.9 | 0.223 |
HTN | 96 (37.4) | 11 (4.1) | <0.001 |
DM | 44 (17.1) | 6 (2.2) | <0.001 |
Cause of donor death, CVA | 196 (76.3) | 167 (62.1) | <0.001 |
eGFR (mL/min/1.73 m2) | |||
Baseline | 79.7 ± 20.1 | 87.8 ± 28.9 | 0.001 |
At allocation | 51.6 ± 29.6 | 94.9 ± 44.6 | <0.001 |
CKD stage 3 or above stage | 174 (67.7) | 83 (30.9) | <0.001 |
AKI | 178 (69.3) | 115 (42.8) | <0.001 |
Stage 1 | 61 (23.7) | 52 (19.3) | |
Stage 2 | 55 (21.4) | 27 (10.0) | |
Stage 3 | 62 (24.1) | 36 (13.4) | |
ECD | 148 (57.6) | 1 (0.4) | <0.001 |
Recipient | 338 | 319 | |
Transplant year | 0.004 | ||
1996–2005 | 0 (0) | 8 (2.5) | |
2006–2010 | 44 (13.0) | 55 (17.2) | |
2011–2016 | 294 (87.0) | 256 (80.3) | |
Age at KT (yr) | 51.3 ± 10.1 | 47.6 ± 9.8 | <0.001 |
Sex, male:female | 201:137 | 188:131 | 0.937 |
BMI (kg/m2) | 23.3 ± 3.5 | 23.0 ± 4.1 | 0.297 |
HTN | 290 (85.8) | 263 (82.4) | 0.242 |
DM | 82 (24.3) | 55 (17.2) | 0.028 |
Dialysis duration before KT (yr) | 7.3 ± 11.7 | 8.8 ± 8.6 | 0.289 |
Previous KT | 25 (7.4) | 45 (14.1) | 0.008 |
Cause of ESRD | 0.003 | ||
Glomerulonephritis | 142 (42.0) | 156 (48.9) | |
DM | 70 (20.7) | 44 (13.8) | |
HTN | 70 (20.7) | 45 (14.1) | |
Others | 56 (16.6) | 74 (23.2) | |
Cold ischemic time (min) | 247.9 ± 118.7 | 254.2 ± 129.8 | 0.531 |
HLA mismatch number | 3.8 ± 1.5 | 3.5 ± 1.5 | 0.014 |
Induction | 0.017 | ||
Basiliximab | 224 (66.3) | 239 (74.9) | |
ATG | 114 (33.7) | 80 (25.1) | |
Major immunosuppressant, tacrolimus:cyclosporine | 335 : 3 | 312 : 6 | 0.251 |
PRA > 50 % | 50 (14.8) | 64 (20.1) | 0.048 |
Follow-up duration (mo) | 44.1 ± 28.7 | 52.2 ± 39.9 | 0.003 |
Data are expressed as number only, mean ± standard deviation, or number (%).
eGFR is calculated using Chronic Kidney Disease Epidemiology Collaboration.
AKI, acute kidney injury; ATG, antithymocyte globulin; BMI, body mass index; CKD, chronic kidney disease; CVA, cerebrovascular accident; DM, diabetes mellitus; ECD, expanded criteria donor; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; HLA, human leukocyte antigen; HTN, hypertension; KDPI, Kidney Donor Profile Index; KT, kidney transplantation; PRA, panel-reactive antibody.
Comparison of clinical and laboratory parameters according to AKI in high or low KDPI donor KTR
Variable | High KDPI-KTR |
Low KDPI-KTR |
||||
---|---|---|---|---|---|---|
Non-AKI-DDKT | AKI-DDKT | p-value | Non-AKI-DDKT | AKI-DDKT | p-value | |
Donor | 79 | 178 | 154 | 115 | ||
Age at KT (yr) | 56.2 ± 10.0 | 54.5 ± 8.3 | 0.173 | 34.8 ± 13.7 | 36.4 ± 10.7 | 0.261 |
Sex, male:female | 44:35 | 127:51 | 0.016 | 107:47 | 90:25 | 0.126 |
BMI (kg/m2) | 23.3 ± 3.3 | 23.1 ± 3.1 | 0.653 | 22.2 ± 3.9 | 24.1 ± 4.0 | <0.001 |
HTN | 41 (51.9) | 55 (30.9) | 0.002 | 8 (5.2) | 3 (2.6) | 0.362 |
DM | 14 (17.7) | 30 (16.9) | 0.859 | 4 (2.6) | 2 (1.7) | > 0.999 |
Cause of donor death, CVA | 56 (70.9) | 140 (78.7) | 0.024 | 92 (59.7) | 75 (65.2) | 0.377 |
eGFR (mL/min/1.73 m2) | ||||||
Baseline | 81.0 ± 27.0 | 45.4 ± 26.6 | <0.001 | 102.3 ± 34.5 | 59.0 ± 36.0 | <0.001 |
At allocation | 77.7 ± 24.7 | 34.0 ± 21.0 | <0.001 | 106.7 ± 31.4 | 50.5 ± 32.0 | <0.001 |
CKD stage 3 or above stage | 37 (46.8) | 85 (47.8) | 1 | 56 (36.4) | 56 (48.7) | 0.046 |
ECD | 39 (49.4) | 109 (61.2) | 0.1 | 0 | 1 (0.9) | 0.428 |
Recipient | 99 | 239 | 171 | 148 | ||
Transplant year | 0.157 | 0.098 | ||||
1996–2005 | 0 (0) | 0 (0) | 7 (4.1) | 1 (0.7) | ||
2006–2010 | 17 (17.2) | 27 (11.3) | 34 (19.9) | 21 (14.2) | ||
2011–2016 | 82 (82.8) | 212 (88.7) | 130 (76.0) | 126 (85.1) | ||
Age at KT (yr) | 51.4 ± 10.7 | 51.3 ± 9.9 | 0.878 | 47.0 ± 8.8 | 48.3 ± 10.7 | 0.261 |
Sex, male:female | 60:39 | 141:98 | 0.809 | 103:68 | 85:63 | 0.649 |
BMI (kg/m2) | 23.3 ± 3.4 | 23.3 ± 3.5 | 0.981 | 22.7 ± 3.2 | 23.4 ± 4.9 | 0.141 |
HTN | 84 (84.8) | 206 (86.2) | 0.735 | 141 (82.5) | 122 (82.4) | > 0.999 |
DM | 18 (18.2) | 64 (26.8) | 0.097 | 29 (17.0) | 26 (17.6) | 0.883 |
Dialysis duration before KT (yr) | 7.0 ± 4.5 | 8.3 ± 13.6 | 0.895 | 9.0 ± 9.8 | 8.6 ± 7.1 | 0.728 |
Previous KT | 6 (6.1) | 19 (7.9) | 0.652 | 18 (10.5) | 27 (18.2) | 0.054 |
Cause of ESRD | 0.290 | 0.022 | ||||
Glomerulonephritis | 45 (45.5) | 97 (40.6) | 95 (55.6) | 61 (41.2) | ||
DM | 15 (15.2) | 55 (23.0) | 24 (14.0) | 20 (13.5) | ||
HTN | 19 (19.2) | 51 (21.3) | 23 (13.5) | 22 (14.9) | ||
Others | 20 (20.2) | 36 (15.1) | 29 (17.0) | 45 (30.4) | ||
Cold ischemic time (min) | 250.2 ± 112.6 | 247.0 ± 121.4 | 0.828 | 262.3 ± 124.7 | 245.1 ± 135.2 | 0.257 |
HLA mismatch number | 3.7 ± 1.6 | 3.8 ± 1.4 | 0.541 | 3.5 ± 1.5 | 3.5 ± 1.4 | 0.634 |
Induction | <0.001 | 0.001 | ||||
Basiliximab | 83 (83.8) | 141 (59.0) | 141 (82.5) | 98 (66.2) | ||
ATG | 16 (16.2) | 98 (41.0) | 30 (17.5) | 50 (33.8) | ||
Main immunosuppressant, tacrolimus:cyclosporine | 97:2 | 238:1 | 0.206 | 165:6 | 147:1 | 0.222 |
PRA > 50% | 13 (13.1) | 37 (15.5) | 0.864 | 32 (21.6) | 32 (23.0) | 0.779 |
Data are expressed as number only, mean ± standard deviation, or number (%).
eGFR is calculated using Chronic Kidney Disease Epidemiology Collaboration.
AKI, acute kidney injury; ATG, antithymocyte globulin; BMI, body mass index; CKD, chronic kidney disease; CVA, cerebrovascular accident; DDKT, deceased donor kidney transplantation; DM, diabetes mellitus; ECD, expanded criteria donor; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease, HLA, human leukocyte antigen; HTN, hypertension; KDPI, Kidney Donor Profile Index; KT, kidney transplantation; KTR, kidney transplant recipient; PRA, panel-reactive antibody.
Comparison of clinical outcomes according to AKI in high or low KDPI donor KTR
Variable | High KDPI-KTR |
Low KDPI-KTR |
||||
---|---|---|---|---|---|---|
Non-AKI-DDKT | AKI-DDKT | p-value | Non-AKI-DDKT | AKI-DDKT | p-value | |
Causes of graft failure | 0.170 | 0.952 | ||||
Acute rejection | 4 (36.4) | 8 (40.0) | 6 (54.5) | 3 (42.9) | ||
Chronic rejection | 1 (9.1) | 8 (40.0) | 1 (9.1) | 1 (14.3) | ||
Recurrent glomerulonephritis | 2 (18.2) | 2 (10.0) | 1 (9.1) | 0 (0) | ||
Ischemia | 0 (0) | 0 (0) | 2 (18.2) | 2 (28.6) | ||
Infection | 1 (9.1) | 1 (5.0) | 0 | 1 (14.3) | ||
BK virus-associated nephropathy | 3 (27.3) | 1 (5.0) | 1 (9.1) | 0 (0) | ||
Causes of death | 0.530 | > 0.999 | ||||
Cardiovascular disease | 2 (50.0) | 4 (28.6) | 2 (16.7) | 0 (0) | ||
Cerebrovascular accident | 0 | 1 (7.1) | 0 (0) | 0 (0) | ||
Infection | 1 (25.0) | 5 (35.7) | 5 (41.7) | 3 (100) | ||
Malignancy | 0 (0) | 1 (7.1) | 2 (16.7) | 0 (0) | ||
Gastrointestinal bleeding | 1 (25.0) | 0 | 1 (8.3) | 0 | ||
Unknown | 0 (0) | 3 (21.4) | 2 (16.7) | 0 |
Data are expressed as number (%).
KDPI, Kidney Donor Profile Index; KTR, kidney transplant recipient; AKI, acute kidney injury; DDKT, deceased donor kidney transplantation
Odds ratios (OR) for allograft failure on the status of AKI or high KDPI donor in deceased donor
Unadjusted OR (95% CI) | p-value | Adjusted OR |
p-value | p-value for interaction | |
---|---|---|---|---|---|
AKI-KT | 0.884 (0.422–1.849) | 0.742 | 1.011 (0.484–2.114) | 0.976 | 0.088 |
AKI stage 3-KT | 1.349 (0.701–2.596) | 0.370 | 1.357 (0.583–3.155) | 0.479 | 0.002 |
High KDPI-KT | 2.304 (1.262–4.205) | 0.007 | 3.096 (1.642–5.838) | <0.001 |
AKI, acute kidney injury; CI, confidence interval; KDPI, Kidney Donor Profile Index; KT, kidney transplantation.
Adjusted by recipient age, transplant year, transplant center, recipient hypertension, acute rejection, panel-reactive antibody of >50%, human leukocyte antigen mismatch, and induction immunosuppressant.
An interaction between AKI in deceased donors and high KDPI deceased donors for allograft failure.
An interaction between AKI stage 3 in deceased donors and high KDPI deceased donors for allograft failure.